The Impact of a Program for Control of Asthma in a Low-Income Setting by Alvaro A. Cruz et al.
ORIGINAL ARTICLE
The Impact of a Program for Control of Asthma in a
Low-Income Setting
Alvaro A. Cruz, MD, PhD,1 Adelmir Souza-Machado, MD, PhD,2 Rosana Franco, MD, PhD,3
Carolina Souza-Machado, MSc,4 Eduardo V. Ponte, MD, PhD,5 Pablo Moura Santos, MSc,5
and Maurício L. Barreto, MD, PhD6
Abstract: The prevalence of asthma is increasing in developing
countries and the burden of uncontrolled asthma affects patients,
families, and the health system. This is to summarize, evaluate, and
discuss previous reports on the impact of a targeted and compre-
hensive approach to the most severe cases of asthma in a low-
income setting. A Program for Control of Asthma (ProAR) was
developed in Salvador, Bahia, Brazil, prioritizing the control of
severe asthma. By facilitating referrals from the public health system
and providing proper multidisciplinary but simple management
including education and medication, for free, the Program enrolled
2385 patients in 4 reference clinics. They are offered regular follow
up and discharged back to primary health care only when asthma
control can be maintained without requirement of a combination of
an inhaled corticosteroid and a long-acting 2 agonist. ProAR has
markedly reduced health resource utilization and decreased the rate
of hospital admissions because of asthma in the entire City (2.8
million inhabitants) by 74%. Moderate to severe rhinitis was asso-
ciated with lack of control of asthma. The average income of the
families in the ProAR was US$2955 a year, and they spent 29% of
all their income attempting to control the severe asthma of one
member, a unbearable expenditure for a low-income family. The
ProAR was shown to be cost-effective, reducing costs to the public
health system (US$387 patient/year) and the families (US$789
patient/year). In a low-income setting of Brazil, an intervention
prioritizing the control of severe asthma was feasible, effective, and
reduced costs.
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INTRODUCTION
Asthma is associated with emergency room visits, risk ofhospitalizations, and deaths. Asthma exacerbations place
a considerable burden on the health care system.1 According
to World Health Organization (WHO) estimates, 300 million
people have asthma and 250,000 die every year.2 Most of the
deaths are preventable with treatment, which is often not
affordable or available in developing countries.
Surveys using the ISAAC (International Study of
Asthma and Allergy in Childhood) methodology conducted
in 3 cities in Bahia–Brazil demonstrate a high prevalence of
symptoms of asthma: 24.6% in Salvador, 21.6% in Feira de
Santana, and 30.5% in Vitoria da Conquista, among adoles-
cents.3 In Recife, Pernambuco, Brazil, 19.1% of the adoles-
cents have symptoms of asthma.3 Asthma is one of the
leading causes of admissions and emergency room visits in
Bahia and Pernambuco, as it is in the country in general.4 Some
3000 people die of asthma every year in Brazil,5 as proper
treatment is not used by the majority of those who need.6
A global evaluation of trends in prevalence of asthma
from surveys repeated on average 7 years apart with the same
questionnaire (ISAAC) and methods in 56 countries indicates
it has reached a high plateau in many of them, including
Brazil, which has figures for prevalence of asthma similar to
those of the United States. However, it seems to continue to
increase in various developing countries such as South Af-
rica, Kenya, Nigeria, Algeria, Morocco, Tunisia, China, In-
donesia, Iran, Pakistan, Argentina, Mexico, Romania, Russia,
and Ukraine.7 In Maputo, Mozambique, a recent survey
found 13% of the adolescents to have symptoms of asthma.8
In addition, in this African City asthma is one of the leading
causes of emergency room visits and hospital admissions. An
analysis of the current situation and a forecast of the short-
medium term perspectives bring no reason for optimism.
Despite remarkable advances in the understanding of the
mechanisms involved in the pathogenesis of asthma and the
development of effective alternatives for treatment, the inter-
action between genetic predisposition and multiple complex
environmental factors leading to varied phenotypes,9,10 has
not allowed scientists to devise clearly its causality. There-
fore, no effective strategy for large-scale prevention is avail-
able at the moment, and the prevalence of asthma is likely to
continue to grow in developing countries as their populations
adopt a westernized urban lifestyle, which has repeatedly
shown to be associated to higher risk.11 Severe asthma rep-
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resents some 10% of all asthma cases but accounts for most
of the health resource utilization, morbidity, and mortality
related to the disease.
As the complex causality of asthma is not fully under-
stood, neither are there clear associations between pheno-
types and specific risk factors, an effective and generalizable
strategy for primary prevention is yet to be identified. Sec-
ond-hand tobacco smoke exposure is currently the only
avoidable exposure for which there is evidence to support
population intervention. A series of systematic reviews of
observational studies evaluated the relation between second-
hand tobacco smoke exposure and respiratory diseases. They
generally reported an increased risk of asthma, wheeze, and
chronic cough in children from families where a parent
smoked. Second-hand smoke increases the severity and fre-
quency of symptoms in children with asthma.12
Several randomized trials of birth cohorts evaluated the
effect of multifaceted interventions on the development of al-
lergy and/or asthma. In these trials, families of children consid-
ered to be at high risk of developing allergy and/or asthma were
randomly assigned to interventions or usual care. Five studies
reported results after 3 to 8 years of follow-up. Interventions
were associated with lower risk of wheezing.13
Reduction of exposure to house dust mites for preven-
tion of asthma, as a single measure, is ineffective. A system-
atic review assessed the efficacy of house dust mite avoidance
measures in patients with asthma14 and 2 additional random-
ized trials published afterward confirmed these findings.15,16
However, most of the randomized trials that examined multifac-
eted interventions to reduce environmental allergen exposure in
children with atopic asthma found fewer days with symptoms,
unscheduled clinic visits, and less use of beta-agonist inhalers in
the intervention group, compared with the controls.17
Evidence on benefits of changes in lifestyle including
diet18 and physical activity19 on subjects with asthma are still
scarce to support clear recommendations aimed at prevention
of asthma. Among subjects with asthma who smoke, cessa-
tion is clearly beneficial.20
There is limited information on the impact of popula-
tion-based interventions for asthma control, but some studies
from developed and developing countries indicate it is cost-
effective. Most asthma exacerbations can be quickly relieved
with a combination of inhaled salbutamol and prednisolone.
These medications or similar products are commonly the only
options for treatment of asthma available free of charge in
developing countries. However, they are not appropriate to
control symptoms of persistent asthma. A glucocorticosteroid
for inhalation, such as beclomethasone, listed as an essential
medicine by WHO,21 controls the airway inflammation and
persistent symptoms of asthma, avoiding exacerbations, hos-
pital admissions, and deaths.22 Inhaled corticosteroids, within
the recommended doses, are safe enough to be used long
term.23 For cases of moderate to severe asthma, a combina-
tion of a long acting bronchodilator and an inhaled cortico-
steroid is more effective than the corticosteroid alone,24 and
therefore has been recommended by current guidelines.25,26
The first large scale national program based on pre-
scriptions of inhaled corticosteroids for control of persistent
asthma implemented and evaluated was the Finnish National
Asthma Program, undertaken from 1994 to 2004 aiming to
reduce the burden of asthma to individuals and society. The
action focused on implementation of new knowledge, espe-
cially for primary care. The number of hospital days fell by
54% from 1993 to 2003. In 1993, 7212 patients received a
disability pension and it was reduced to 1741 in 2003. The
total increasing costs with asthma begun to decline, being
reduced from 218 million euro to 213.5 million euro per year.
Costs per patient per year have decreased 36%.27 According
to the authors, the key for the success was an effective
network of focal points for asthma and an evaluation strategy.
A multicentric controlled study among inner-city children
with asthma in the US had favorable outcomes.28 Observa-
tions after interventions on pediatric asthma in 2 cities in
Brazil also reported reduction in morbidity.29 The results
obtained in Finland after the implementation of the asthma
program could potentially be reproduced in affluent societies,
and it is likely to work in low- and middle-income countries
as well. However, there is no evidence of the feasibility of the
implementation and evaluation of the impact of such country
wide approach elsewhere.
In Brazil, as in most Latin American countries, despite
several attempts, there is no countrywide strategy for asthma
prevention or outpatient management in public health facilities
in place. Isolated nonstandardized initiatives restricted to a few
cities and focused on distinct ages and asthma severity groups
have been implemented. The combination of high prevalence
and limited access to secondary prevention may cause high
morbidity and unacceptable mortality. Morbidity resulting
from asthma is not easy to measure, but hospital admission
rates disclose the most severe episodes and consequently
represent a relevant indicator of the burden of uncontrolled
asthma in a population that has access to hospitals.
This is a review paper, aiming to summarize, evaluate,
and discuss the impact of a public health intervention on
hospitalizations and costs related to asthma in Salvador,
Bahia, Brazil. It might be taken as a case study of feasibility
and comparative effectiveness of knowledge translation prac-
tices for asthma control in low-income settings.
METHODS
Salvador City is the capital of the state of Bahia,
located in northeastern region of Brazil with a population of
2.8 million. The proportional National Gross Product per
capita estimate for Salvador is $2700 US dollars/year. A
major part of the population has no supplementary health
insurance and is covered only by the universal public health
policies. ProAR encompass a public health intervention for
prevention and control of asthma followed by various obser-
vational studies to investigate the outcomes of the interven-
tion at individual and population levels. As there were no
human neither financial resources to tackle the problem in
general, during the initial years, the project aimed at the
control of severe asthma (2385 patients registered until April
2007) by providing free medication and multidisciplinary
care in 4 governmental reference centers in the City to
low-income patients. In addition, ProAR has offered training
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to primary health care teams for prevention and control of
mild to moderate asthma and educational sessions for the
patients and families.
ProAR was launched in 2003 and has developed 3
categories of core activities: health care, capacity building,
and research. It is lead by a team of academicians which
interact with all levels of public health management to pro-
vide appropriate multidisciplinary care including education
for health and medication, for free. The central reference
clinic and administration of ProAR are located within facil-
ities of the Department of Health of the City of Salvador,
Bahia, which has a memorandum of understanding for coop-
eration with UFBA, and also provides part of ProARs health
care work force.
Current ProAR Approach for Asthma Control
Facing the lack of resources to initiate a full scale
intervention for prevention and control of asthma, the initia-
tors of ProAR decided to start a program focusing on the most
severe patients by opening up reference centers to offer
specialized care, patients education, and pharmaceutical as-
sistance. A concommitant series of 14 workshops (6 hours
each) were carried out aiming to raise recognition of the
burden of asthma, to increase awareness on the availability of
effective interventions, build capacity for management of
mild and moderate cases and to stimulate referrals of severe
cases, having in the audience primary health care physicians,
registered nurses, pharmacists, managers, and policy makers.
More than 500 attendants were registered from 2005 to 2007.
ProAR takes advantage of policies of the Ministry of
Health for reimbursement of expenditures with medications
in cases of severe asthma. The reference clinics are accessible
to all population and free at the point of use. In accordance to
current guidelines,26 patients with severe asthma are treated
with regular use of combined inhaled corticosteroid and a
long-acting 2 agonist for maintenance, and short acting
inhaled 2 agonist for rescue, as needed. Patients with per-
sistent rhinitis receive topical nasal beclomethasone concom-
itantly. Educational sessions for patients and family members
emphasize prevention and early control of exacerbations. A
particular effort is placed on improving compliance to treat-
ment and proper use of inhalers.
Evaluation of the Impact of ProAR at the
Individual Level, An Observational Cohort
On the first day of medical evaluation in ProAR the
patients are asked about the number of hospital admissions,
emergency room visits, cycles of systemic corticosteroids,
and school/work days missed because of an asthma exacer-
bation within the 12 months before their enrollment in the
program, according to pre-established standard forms filled
out by the attending physician or nurses. In the first year of
the follow-up period, visits are scheduled 3 months apart, at
most. During each medical visit, the patients are asked about
the occurrence of the events above mentioned during the
follow-up, and another specific standardized form is filled out
to register this information, which is subsequently entered
into a database. The variables are expressed as total number
of events and in number of events per patient per year.
The diagnosis of severe asthma follows the guidance of
Global Initiative for Asthma (GINA).30 A Spirometry is
mandatory, performed with a KoKo spirometer (Software
PDS Instrumentation, Inc., Louisville, CO), according to the
norms of the American Thoracic Society,31 using the param-
eters of normality devised by Pereira et al.32
To estimate rates of adherence to treatment in patients
with severe asthma, to identify predictors of adherence to
treatment and evaluate the relationship between adherence to
treatment, clinical and functional parameters, a random sub-
set of patients enrolled was followed during 180 days to
objectively evaluate adherence.
Evaluation of the Impact of ProAR in the Entire
City (2.8 Million Inhabitants)
Data on hospitalization in the public health system has
been collected from all events registered in the city of
Salvador. Events do not represent the number of hospitalized
patients, but the number of admissions occurred in Salvador
hospitals. For comparison, we collected the same information
relative to the city of Recife, northeast of Brazil.
Data on hospital admissions events from every month
can be obtained from the national statistical database (SIH/
DATASUS, IBGE www.ibge.gov.br). Relevant studies using
this same database have already been published.33 The num-
ber of events of hospitalizations because of asthma is col-
lected according to place of residence (City), ICD-10, age
group, and sex. The number of hospitalization events are
converted in hospitalization rates and analyzed separately
according to sex and 2 age groups: 10 years old and 10
years old. The number of units of inhaled corticosteroids and
fixed combination of corticosteroid and long-acting 2 ago-
nist bronchodilator are obtained from the pharmacies supply-
ing medication to patients from ProAR, for comparison with
health outcomes. Hospitalization rates are obtained dividing
absolute number of events per local and year-by-year popu-
lation of each city, and multiplying by 10,000 (inhabitants).
This procedure was chosen to avoid trends influenced by
migration seasonality, and variations in population numbers
caused by birth and deaths.
Evaluation of Costs of Severe Asthma to
the Families
A sample of 198 consecutive patients with severe
asthma for at least 1 year, referred to ProAR and aged 12 to
75 years old, was selected for detailed evaluation of costs.
Patients typically have continuous asthma symptoms, and
daily limitation to exercise, frequent exacerbations, and night
symptoms, requiring daily use of a bronchodilator. The ma-
jority reported frequent emergency visits, hospitalizations,
and had a low-forced expiratory volume in one second
(FEV1). Some reported admission to intensive care units. The
study design is that of an observational clinical cohort of
patients with severe asthma. We aimed to compare the direct
and indirect costs of treatment for the families before and
after the intervention by ProAR. Patients were recruited when
coming for the first time. At baseline they answer 3 question-
naires: AFCQ (asthma family costs questionnaire), AQLQ
(Asthma Quality of Life Questionnaire),34 and ACQ (Asthma
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Control Questionnaire), which has just been evaluated within
ProAR for accuracy, responsiveness, and reproducibility.35
Family’s costs of severe asthma were measured and com-
pared for the 2 different treatment strategies (regular public
health system care and the intervention by ProAR), using
accounting procedures. Costs are brought up to current values
and the necessary depreciation estimated.
The AFCQ, AQLQ, and ACQ
The AFCQ is used to estimate family’s costs. The
questionnaire has 33 questions about direct and indirect costs
for the treatment of a family member with asthma. It is
divided in 6 sets of items (family income, financial help,
transportation, loss of job or income because of asthma,
medicines, and other expenses). Patients are asked to bring
evidence for their information, such as pay slips or bank
statements, transportation or meals tickets, medicine’s boxes,
or receipts of any purchase or expenditure. The AFCQ reli-
ability and reproducibility were evaluated and confirmed in
asthma among 30 patients before wide utilization. The group
of researchers interested in health economics in ISC UFBA
made it available in Portuguese and English.36
Evaluation of Costs to the Health System and
Cost-Effectiveness of ProAR Strategy
A subsample of 81 patients with severe asthma, from
12 to 75 years old, living in Salvador and its metropolitan
area, were consecutively selected from those attending regu-
larly the central reference outpatient clinic of ProAR for an in
depth analysis of cost-effectiveness. To be included in this
study, patients were required to have more than 1 year of
severe asthma. It is a before and after study (pre-post) of
patients managed in ProAR central reference clinic. The
objective is to compare the estimated cost-effectiveness, for
families and the public health system, of 2 strategies for
management of asthma experienced by the same patients: the
regular asthma care available in the Salvador public health
system and that offered by ProARs intervention. During the
initial visit researchers collected economic and clinical retro-
spective information regarding health resource utilization
because of asthma in the past 12 months. It included patient’s
and family’s income, doctor’s visits, medications, therapeutic
devices and diagnostic tests, emergency room visits, hospi-
talizations, and intensive care admissions because of asthma.
The same information was then collected prospectively on
monthly visits during ProAR follow up and intervention for 1
year, for comparison with the previous year. To compare the
cost-effectiveness of treatment of severe asthma for both strat-
egies (regular public health system care before, and the ProAR
after), the costs for the public health system, for ProAR and for
the families are estimated using accounting procedures. Cost-
effectiveness incremental analysis is performed by comparing
the costs and health results, dividing the difference in costs per
the difference of health results obtained on each strategy.37 A
sensitivity analysis was carried out to ascertain the reliability of
the cost-effectiveness estimates under varied assumptions re-
garding costs of health care.38
RESULTS
The evaluations of the impact of ProAR demonstrate
control of asthma in the individuals enrolled, resulting in
major reduction in health care utilization. An analysis of the
first 269 subjects with severe asthma joining ProAR central
reference clinic to complete 1 year of follow up found a
reduction of 85% in emergency department visits, 90% in
hospitalizations, and 67% in use of oral corticosteroids.39
The analysis of a subsample of 197 patients demon-
strated a median family income of US$2955/year. In 47% of
the cases, a family member had lost a job because of asthma.
Total cost of asthma management took 29% of family income.
After proper treatment asthma control scores improved by 50%
and quality of life by 74%. The income of the families increased
by US$711/year, as their members went back to work. The total
cost of asthma to the families was reduced by a median US$789/
family/year. Consequently, an annual surplus of US$1500/fam-
ily became available (Fig. 1).40
In Salvador, hospital admissions because of asthma de-
clined by 82.3% (1998–2006). A greater proportion of this
reduction (74%) happened after 2003. While there were also
trends for reduction in admissions in Recife, the magnitude was
smaller (22%). The rates of hospitalization because of asthma in
2006 were: 2.25/10,000 inhabitants in Salvador and 17.06 in
Recife. Furthermore, in Salvador, an inverse correlation between
dispensation of inhaled medication for asthma and hospitaliza-
tion rates were found (0.801; P  0.001) (Fig. 2).41
During the initial 12-months of follow-up within the
program, a subsample of consecutive severe cases of asthma
chosen for health economic analysis had 5 fewer days of hos-
pitalization and 68 fewer visits to emergency/nonscheduled
medical visits per year, on average. Asthma control scores
improved by 50% and quality of life by 74%. The annual saving
in public resources was US$387/patient (Table 1).42
A subsample of 557 patients was investigated for the
inter-relation between rhinitis and asthma. During 1 year of
follow-up each patient was evaluated every 3 months with a
FIGURE 1. Family income, family direct and indirect cost
per patient/year due to severe asthma and family annual net
income, before and after ProAR intervention (median 
quartiles). Reprinted with permission from Allergy.40
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record of emergency room visits and supply of topical cortico-
steroids for treatment of asthma and rhinitis. In the 1-year of
follow-up visit, patients were checked for rhinitis diagnosis and
severity and answered questionnaires for asthma symptoms and
quality of life. Eighty-two (15%) patients had no rhinitis, 299
(54%) had mild rhinitis, and 176 (31%) moderate/severe rhinitis.
In logistic regression models, moderate/severe rhinitis was a
strong predictor for any emergency room visit in the follow up
period [odds ratio (OR) 3.83 (2.00–7.35)], for the presence of
uncontrolled asthma after 1 year of follow up [OR 12.68 (1.73–
92.85)], for less than 10% improvement of the airway obstruc-
tion [OR 2.94 (1.48–5.85)], and less than 50% reduction in the
number of emergency room visits [2.90 (1.02–8.26)] in the year
of follow up. It was also associated with a smaller chance of
more than 90% reduction in the number of emergency room
visits [OR 0.27 (0.12–0.60)]. In a multivariate linear regression
model, the severity of rhinitis was positively correlated with a
score of asthma severity and inversely correlated to an index of
quality of life (Table 2).43 Table 3 presents a summary of the
clinical and demographic characteristics of a sample of 557
consecutive patients with severe asthma followed up for 1 year
in ProAR.43
DISCUSSION
Asthma, a global health problem, causes relevant mor-
bidity, numerous preventable deaths and high costs to the
families and to the health systems.1,2 The costs of asthma are
related to severity of disease,1 and hospitalizations represent
50% of all the expenditures with asthma.25,26
Our main findings are: 1) ProAR has reduced health
resource utilization and remarkably reduced the rate of hos-
pital admissions because of asthma in the entire City; 2)
severe asthma leads to a unberable expenditure for low-
income families, ProAR was shown to be cost-effective,
FIGURE 2. Asthma hospitalization rates, number of patients
enrolled in the Program for Control of Asthma in Bahia
(ProAR) and number of dispensed units of medication con-
taining inhaled corticosteroids (ICS)/1000 in Salvador-Bahia,
Brazil, from 2002 to 2006. Reprinted with permission from
European Respiratory Society Journals.41
TABLE 1. Comparison Among Economic Parameters of Two Strategies for Control of Severe Asthma (n  64)
Year Before ProAR (US$)
Median (Quartile)
Year After ProAR (US$)
Median (Quartile) P*
Government annual costs per patient
Cost of outpatient treatment 184 (177/192) 359 (240/471) 0.01
Cost of hospital treatment 590 (78/1330) 0 (0/19) 0.01
Total annual government costs of treatment 750 (286/1462) 363 (255/481) 0.01
Family annual costs of treatment and income
Family income 2768 (1912/4033) 3280 (2191/5050) 0.02
Family expenses with asthma (direct cost) 615 (343/1374) 74 (34/275) 0.01
Proportion of income spent with asthma 29% 2%
Total family costs (direct  indirect) 807 (358/1509) 74 (35/281) 0.01
*Wilcoxon Signed Rank Tests.
Modified from Franco et al.42
TABLE 2. Asthma Severity and Response to Treatment
According to Co-Existence and Severity of Rhinitis
Asthma Severity and
Response to Treatment OR (95% CI)
Any emergency room visit in the follow-up
period
No rhinitis —
Mild rhinitis 1.90 (1.02–3.54)
Moderate to severe rhinitis 3.83 (2.00–7.35)
Uncontrolled asthma*
No rhinitis —
Mild rhinitis 1.23 (0.17–8.69)
Moderate to severe rhinitis 12.68 (1.73–92.85)
Less than 50% reduction in emergency room
visits**
No rhinitis —
Mild rhinitis 1.90 (0.72–5.04)
Moderate to severe rhinitis 2.90 (1.02–8.26)
Less than 10% improvement in FEV1
No rhinitis —
Mild rhinitis 1.84 (0.98–3.44)
Moderate to severe rhinitis 2.94 (1.48–5.85)
Adjusted for sex, age, VEF1, daily dose of inhaled corticoid, number of emergency
room visits in the year before enrollment; *There were 330 patients available for this
analysis; **considering only 443 patients with emergency visits.
Modified from Ponte et al. (43).
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reduced costs to the public health system and to the families
(by US$789/patient/year); 3) moderate to severe rhinitis was
associated with lack of control of asthma.
A limitation of our study is that information from the
year before intervention was collected retrospectively from
patient reports. It would not be ethical to have a parallel
control group of severe asthmatics followed up without
access to ProAR, once free preventive inhaled medication
was made available. Therefore, the only way we could
study patients inside and outside the program was com-
paring their own profile before and after the intervention.
In this study, patients apparently had no difficulty to recall
hospitalizations, emergency room visits, income, financial
help, medicine prices, and transportation expenses. They
were able to recall and to present evidence of their recent
expenses with medicine, bringing priced medicine boxes
or drugstore receipts, and medical reports and prescrip-
tions from hospitalizations and emergency visits as well.
In favor of findings of this report, it shall be considered
any possible loss of information related with the retrospec-
tive period, acts toward decreasing the estimated economic
costs during this period. Therefore the impact of the
asthma on the family income can be even greater than
presented here. The presence of an interviewer might have
influenced the patient’s answers. However, this was
needed as the majority of patients had low educational
level and some were illiterate. The interviewer was trained
to avoid influencing the answers, and was the same for all
patients throughout all the visits.
Although asthma hospitalizations have decreased in
recent years in Brazil, in large urban centers such as Recife
and Salvador, they seem to decrease slowly since 1998. In
Salvador, the implementation of ProAR in 2003 has likely
accelerated these declining trends.
The most important novel observation of this study is
the rapid reduction in asthma admissions in a City of 2.8
million inhabitants, after a very focused intervention tar-
geting patients at greater risk. This observation needs to be
reproduced in other locations, as it would be of remarkable
importance to public health in countries with high morbid-
ity because of asthma and limited resources. We speculate
that the most important factors that determined our favor-
able results were: 1) considerable proportion of patients
with severe asthma with no assess to good quality care
including affordable medication at baseline; 2) establish-
ment of treatment with the most effective and safe medi-
cations; 3) education program to increase compliance to
proper medication use; 4) referral system made easy to
patients and health services. Given these 4 conditions, it
seems unlikely that a similar intervention may fail.
The future of ProAR depends on renewed support from
research agencies and public health authorities in Brazil. It is
fully nested in the public health system and has all prerequi-
sites of sustainability: qualified human resources, infrastruc-
ture, demand, effectiveness, and efficiency. If adequate sup-
port is obtained the severe asthma program should be
expanded to all other cities in the state of Bahia, and its
experts should help the State Department of Health in build-
ing capacity of the primary health care professionals to
handle the milder forms of the disease.
In this study, moderate/severe rhinitis was strongly
associated with parameters that indicate greater asthma se-
verity. This was demonstrated by the increased risk of any
emergency room visit for acute asthma in the year of follow
up, poor asthma control, less reduction in the number of
emergency room visit in the follow up period, and limited
improvement in airway obstruction after 1 year of follow up.
Patients with mild rhinitis also had an increased risk of any
emergency room visit for acute asthma and a smaller reduc-
tion in the number of emergency room visits in the year of
follow up. These results are in accordance with data from
previous retrospective studies, which observed more severe
symptoms of asthma and increased risk for emergency room
visits and for hospital admissions for acute asthma among
patient with concomitant rhinitis.44–46
The consequence of increased asthma severity is a
compromised quality of life and increased cost of asthma.
In this study, it was also possible to demonstrate that
rhinitis severity contribute to a decreased asthma related
quality of life in a multivariate model. Rhinitis severity
was positively correlated with the annual cost of asthma.
Although the present study reinforces the association be-
tween rhinitis, asthma severity, and cost of asthma, it is not
possible to conclude that rhinitis is the cause of asthma
severity and increased cost. The possibility that they are
both the manifestation of one only disease may be the most
important factor underlying these strong associations. The
proposed paradigm of unicity of disease in asthma and
rhinitis47 would imply the existence of an intrinsic link
between the severity of the symptoms in the upper and in
the lower airways.
TABLE 3. Clinical and Demographic Characteristics of a
Sample of 557 Patients With Severe Asthma Followed-Up
for 1 Year in ProAR (Program for Control of Asma in
Bahia, Brazil)
Female gender (%) 438 (78)
Age (years) 49 (38–59)
Body mass index 35 (%) 43 (10)
Illiterate patients (%) 60 (14)
Smoking history 10 pack years (%) 68 (12)
Rhinitis diagnosis (%)
No rhinitis 82 (15)
Mild 299 (54)
Moderate to severe 176 (31)
Age at first asthma symptoms (years) 13 (5–29)
Duration of asthma symptoms (years) 28 (17–47)
Inhaled corticosteroid for asthma 800 mcg/d (%) 470 (84)
Any emergency room visit in the year of follow up (%) 265 (47)
Positive skin prick test (%) 231 (56)
FEV1 prebronchodilator at last study visit (% predict) 68 (54–82)
FVC prebronchodilator at last study visit (% predict) 91 (81–102)
Results are expressed in numbers (proportions) or in medians (percentiles 25–75).
Modified from Ponte et al. (43).
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It is not possible to conclude that the treatment of
rhinitis will reduce asthma cost either. This is an important
issue, because the concept that rhinitis impacts on asthma
control is largely accepted. Although the interrelationship
between asthma and rhinitis is largely demonstrated, the
impact of rhinitis treatment on asthma is still a matter of
investigation. Our results suggest that future research should
focus on evaluating the cost-effectiveness of adding nasal
corticosteroids for the treatment of severe asthma in patients
with moderate/severe rhinitis.
Some messages to policy makers should arise from the
experience of ProAR, in line with the vision of the Global
Alliance against Chronic Respiratory Diseases of “a world
where all people breathe freely”2: 1) recommendations for the
treatment of severe and/or uncontrolled asthma from best
evidence-based current asthma guidelines are applicable and
effective in low-resource settings; 2) free management of the
most severe cases of asthma according to the guidelines, in
reference centers, not only restores the patient’s capability to
breathe, but also alleviate the economical suffocation of poor
families further impoverished by the cost of the ailment; 3)
the strategy of ProAR, in Salvador, Bahia, Brazil, reduced
health resource utilization, decreased the costs with asthma to
the public health system, and could be adapted to similar
settings elsewhere.48 This provides a remarkable opportunity
to use current knowledge and available technology to atten-
uate social inequalities.
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